Dr. Reddy’s Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
Financial Results:
Dr Reddys Laboratories Ltd reported Revenues for Q3FY25 of ₹8,381.00 Crores up from ₹7,237.00 Crore year on year, a rise of 15.81%.
Total Expenses for Q3FY25 of ₹6,661.00 Crores up from ₹5,627.00 Crores year on year, a rise of 18.38%.
Consolidated Net Profit of ₹1,404.00 Crores up 1.67% from ₹1,381.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹16.94, up 2.29% from ₹16.56 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
